You can now read 10 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe

Business

Biogen Idec’s ALS drug falls short in trials

Biogen Idec. Inc. has halted development of an experimental drug to treat the devastating neurodegenerative disorder known as Lou Gehrig’s disease, saying Thursday that it proved ineffective in a late-stage ­clinical trial.

The decision deals a blow to an estimated 30,000 Americans who suffer from amyotrophic lateral sclerosis, or ALS, a fatal condition for which there is no cure.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week